<DOC>
	<DOCNO>NCT00030082</DOCNO>
	<brief_summary>RATIONALE : Heating melphalan several degree body temperature infusing affect area directly around tumor may kill tumor cell . PURPOSE : Phase I trial study effectiveness hepatic arterial infusion melphalan treat patient unresectable liver cancer .</brief_summary>
	<brief_title>Hepatic Arterial Infusion With Melphalan Treating Patients With Unresectable Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxicity maximum tolerate dose hepatic arterial infusion melphalan patient unresectable liver cancer . - Determine regional systemic toxic effect drug patient . - Determine pharmacokinetics drug patient . OUTLINE : This dose-escalation study . Patients undergo percutaneous hepatic arterial infusion , use double balloon catheter inferior vena cava isolate circulation liver , melphalan 30 minute day 1 . Treatment may repeat toxic effect grade 2 less . Patients undergo stag 4 week completion second treatment . Patients may receive 2 additional treatment . Cohorts 3-6 patient receive escalate dos melphalan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 12 additional patient treat melphalan recommend dose . Patients follow every 3 month 2 year every 4 month 1 year . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable cancer parenchyma liver Liver metastases allow Limited unresectable extrahepatic disease ( include limit follow ) allow provide lifethreatening component progressive disease liver : Up 4 pulmonary nodule less 1 cm diameter Retroperitoneal lymph node less 3 cm diameter Fewer 10 skin subcutaneous metastasis le 1 cm diameter Asymptomatic bone metastasis palliate radiotherapy Solitary metastasis site resect Prior therapy intrahepatic perfusion without hepatic arterial infusion floxuridine allow provided patient radiographic partial response 3months duration PATIENT CHARACTERISTICS : Age : 14 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count great 100,000/mm^3 Absolute neutrophil count least 1,300/mm^3 Hematocrit great 27 % Hepatic : Bilirubin great 2.0 mg/dL PT within 2 second upper limit normal No biopsyproven cirrhosis evidence portal hypertension history , endoscopy , radiologic study Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No prior congestive heart failure LVEF le 40 % Pulmonary : No chronic obstructive pulmonary disease No chronic pulmonary disease FEV_1 least 30 % predict DLCO least 40 % predict Other : Weight great 35 kg HIV negative No active infection No severe allergic reaction iodine contrast control antihistamine steroid No know prior hypersensitivity reaction melphalan Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 month since prior biologic therapy malignancy recover Chemotherapy : See Disease Characteristics At least 1 month since prior chemotherapy malignancy recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 1 month since prior radiotherapy malignancy recover Surgery : Not specify Other : No concurrent chronic anticoagulants No concurrent immunosuppressive drug</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>